Diagnosis and treatment from the migraine experts

Continuous treatment improvements: after you receive your initial treatment plan, we keep screening your migraine and genetic information to match you with better treatment options once new evidence becomes available. Treatment improvements are included in your membership. You and your doctor will be notified. Our goal is to ensure that you always receive the best migraine care possible.

After you accept your treatment plan (you'll be notified via email), we ship a 90-day supply of your medication direct to your door. Payments are billed every 30 days after initial order. Memberships auto-renew every three months. Easy cancellation.

100% refund guarantee if no treatment recommendation can be issued or you are not happy with Mable.

To ensure the scientific rigor of our testing process, we only use scientifically backed pharmacogenetic markers published by the FDA and the Clinical Pharmacogenetics Implementation Consortium (CPIC). We regularly update our testing menu, once new solid scientific evidence becomes available.

In headache specialist clinics, most preventative migraine medications are prescribed "off-label". For instance, certain beta-blockers or antidepressants are routinely used to treat migraines. These medications have well documented pharmacogenetic associations and Mable enables physicians to leverage these to guide treatment based on DNA.

These help reduce nausea accompanying a migraine attack.

These are taken at the onset of a migraine attack to stop or reduce the pain. There are some painkillers that are highly specific for migraines. These include many different triptans such as Zolmitriptan, Almotriptan, Rizatriptan, Frovatriptan and Naratriptan. For this group of medications, there are no known genetic markers available to date. Fortunately, the choice of acute treatment can be informed by your specific migraine symptoms and medical history.

CGRP (Calcitonin Gene-Related Peptide) inhibitors are a new class of medications to prevent and treat acute migraine pain. To date, there are no well established genetic markers to help predict a person's response to this group of medications. Mable and academic institutions are intensely researching this new field of migraine care and we will incorporate CGRP inhibitors into our testing process once strong scientific evidence becomes available.

Mable's test looks for 350+ SNPs (single nucleotide polymorphisms) that impact your body's response to migraine medications. This approach is called pharmacogenetic testing. Mable uses exclusively scientifically backed pharmacogenetic associations published by the FDA and the Clinical Pharmacogenetics Implementation Consortium (CPIC).
Knowledge of a patient's genotype can be used to guide a therapeutic strategy, determining an appropriate dosage, or assessing the likelihood of benefit or toxicity. We found that 60% of people with migraine have a genetic predisposition that would warrant caution with 8 or more standard migraine medications.

Mable's platform enables physicians for the first time to contextualize this pharmacogenetic information with your unique migraine symptoms in order to create a personalized treatment plan in accordance with your unique physiology.